U.S. Markets close in 3 hrs 52 mins

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1315+0.0021 (+1.66%)
As of 11:49AM EDT. Market open.

Tetra Bio-Pharma Inc.

2742 St. Joseph Boulevard
Unit 200
Orléans, ON K1C 1G5
Canada
343 780 2020
http://www.tetrabiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees31

Key Executives

NameTitlePayExercisedYear Born
Dr. Guy Chamberland M.Sc., Master Herbal, Ph.D.Co-Founder, CEO, Chief Regulatory Officer & DirectorN/AN/A1962
Mr. André Rancourt B.Sc.Co-FounderN/AN/AN/A
Mr. Jean-Francois Boily C.A., CPAChief Financial OfficerN/AN/AN/A
Dr. Graham WoodChief Operating OfficerN/AN/AN/A
Dr. Melanie Edna Mary KellyChief Scientific OfficerN/AN/AN/A
Jennifer McCaugheyVP of Investor RelationsN/AN/AN/A
Mr. Steeve NéronChief Commercial OfficerN/AN/AN/A
Ms. Dania Scott B.Sc.Sr. VP of Commercial StrategyN/AN/AN/A
Mr. Richard GiguereChief Exec. Officer of Tetra Natural Health Inc.N/AN/AN/A
Randy RinguetteProject Director & Member of Advisory BoardN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages development of cannabinoid-based medicines. It develops drugs for chronic pain, which includes SERENITY for cancer cachexia, which is clinical phase 2; REBORN, drug for breakthrough pain, which is in clinical phase 2; and PLENITUDE for advanced cancer pain, which is clinical phase 1. The company also develops PPP003, drug for painful dry eye and uveitis pain, which is in clinical phase 1; and HCC011 for hepatocellular carcinoma.It has collaboration agreements with Aphria Inc.; IntelGenx Corp.; Panag Pharma Inc.; the University of New Brunswick; and Ovensa Inc. The company also has a co-development partnership with Storz & Bickel for the treatment of fibromyalgia. The company was formerly known as GrowPros Cannabis Ventures Inc. and changed its name to Tetra Bio-Pharma Inc. in September 2016. Tetra Bio-Pharma Inc. is headquartered in Orleans, Canada.

Corporate Governance

Tetra Bio-Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.